Sharp receives MHRA approval for Clinical Services Centre of Excellence

Sharp – part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has received approval from the Medicines and Healthcare Product Regulatory Agency (MHRA) to begin production at itsClinical Services Centre of Excellence in Rhymney, Wales.

Following a successful inspection by the MHRA, Sharp can now offer a range ofclinical trial and commercial services from the £9.5 million facility includingprimary and secondary packaging with low humidity control, labelling, storage and distribution, QP services as well ascontrolled drug storage.

The Centre also enables Sharp to offer a broader range of integrated services includingserialisation and Interactive Response Technology (IRT) solutionsfor clinical trial management.

Frank Lis, president of Sharp Clinical Services, said:“The Clinical Services Centre of Excellencein Rhymney has tripled Sharp’s clinical service capacity for the pharmaceutical, biotech and clinical research sectors.

“With the integrated capabilities on offer, the facilityalso better enables us to offer full-service support and meet the increased global demandfor Phase III clinical trials and commercialpharmaceutical services.

“We are dedicated to supporting our customers for years to come and the Rhymney site is a sign of that commitment.”

The MHRA approval comes as Sharp celebrates its 30th year of clinical operations in the UK.

Lis added: “To be able to celebrate two such significant achievements at the same time is testament to the effort and dedication of everyone involved in the success of Sharp.”

Sharp has also invested in a solar panel system at the site that will generate approximately 20% of Sharp Clinical Services’ total annual electricity requirements, further reducing the company’s carbon footprint and increasing environmental performance.

About Sharp
Sharp, part of UDG healthcare, is a global leader in contract packaging and clinical services. Operating from eight state-of-the-art facilities across the US and Europe, Sharp has built an international reputation for delivering cost-effective blister packaging, bottling, secondary assembly and labelling of injectable presentations, compliance packaging, formulation and manufacturing services, label design and printing. We are also a world leader in ’Track and Trace’ and serialization services, with over eleven years’ experience in implementing serialized solutions for our pharma clients.

Sharp Clinical
Sharp Clinical offers a full complement of clinical trial services, including analytical, formulation development, clinical manufacturing and packaging, storage and distribution. Sharp also offers an interactive response technology (IRT) platform which can accommodate simple to complex randomization schemes as well as clinical supply chain management.

During 2018, Sharp Clinical invested $36 million in new dedicated facilities in both the US and the UK and can offer QP services for European distribution. We service every phase of the drug lifecycle from Phase 1 through to commercialization and through our global network of over 30 depots we can distribute to every region of the world. Our highly experienced team will help you optimize every aspect of your clinical trial.